Abstract
There is increasing evidence that polymorphisms of the adenosine 5′ triphosphate membrane transporters ABCB1 (P-glycoprotein, MDR1) may affect expression and function, whereas less information is available about the impact of ABCC2 (multidrug resistance-associated protein (MRP2)) single-nucleotide polymorphisms . Particularly, their role in human kidney for drug elimination and in the etiology of renal cell carcinoma is poorly understood. ABCB1 and ABCC2 mRNA and protein expression levels were determined by real-time polymerase chain reaction or immunohistochemistry in kidney cancer and adjacent unaffected cortex tissue of 82 nephrectomized renal cell cancer (RCC) patients (63 clear-cell RCC (CCRCC), 19 non-CCRCC). The DNA of all patients was genotyped for ABCB1 −2352G>A, −692T>C, 2677G>T/A (Ala893Ser/Thr), and 3435C>T, and ABCC2 −24C>T, 1249G>A (Val417Ile) and 3972C>T. ABCB1 and ABCC2 were less expressed in CCRCC than in normal cortex on mRNA as well as on protein level. Although the overall genotype frequency distribution did not differ between the patients and a matched control group, ABCB1 2677T/A and 3435T genotypes were associated with higher (P=0.02 and P=0.04) and ABCC2 −24 T with lower mRNA levels in normal tissues (0.03). The expression of ABCB1 and ABCC2 was not related to genetic variants in RCC tissue. In a reporter gene assay in HepG2 cells, the ABCC2 −24T construct showed an 18.7% reduced activity (P=0.003). In conclusion, ABCB1 and ABCC2 genotypes modulate the expression in the unaffected renal cortex of RCC patients, possibly contributing to inter-individual differences in drug and xenobiotics elimination. Their role in RCC cancer susceptibility or chemotherapy resistance needs further elucidation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
Abbreviations
- 5′-UTR:
-
5′-untranslated region
- ABC:
-
adenosine 5′ triphosphate-binding cassette
- MDR1:
-
multidrug resistance protein 1
- MRP2:
-
multidrug resistance-associated protein
- P-gp:
-
P-glycoprotein
- SNP:
-
single-nucleotide polymorphism
- PCR/RFLP:
-
polymerase chain reaction/restriction fragment length polymorphism
References
Borst P, Evers R, Kool M, Wijnholds J . The multidrug resistance protein family. Biochim Biophys Acta 1999; 1461: 347–357.
Klein I, Sarkadi B, Varadi A . An inventory of the human ABC proteins. Biochim Biophys Acta 1999; 1461: 237–262.
Konig J, Nies AT, Cui Y, Leier I, Keppler D . Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1999; 1461: 377–394.
Young AM, Allen CE, Audus KL . Efflux transporters of the human placenta. Adv Drug Deliv Rev 2003; 55: 125–132.
Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM . Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39: 361–398.
Schaub TP, Kartenbeck J, Konig J, Vogel O, Witzgall R, Kriz W et al. Expression of the conjugate export pump encoded by the mrp2 gene in the apical membrane of kidney proximal tubules. J Am Soc Nephrol 1997; 8: 1213–1221.
Schaub TP, Kartenbeck J, Konig J, Spring H, Dorsam J, Staehler G et al. Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol 1999; 10: 1159–1169.
Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D . Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999; 55: 929–937.
Juliano RL, Ling V . A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152–162.
Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473–3478.
Johne A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 2002; 72: 584–594.
Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Jaillon P et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 2003; 58: 809–812.
Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W . Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genom 2005; 15: 693–704.
Uwai Y, Masuda S, Goto M, Motohashi H, Saito H, Okuda M et al. Common single nucleotide polymorphisms of the MDR1 gene have no influence on its mRNA expression level of normal kidney cortex and renal cell carcinoma in Japanese nephrectomized patients. J Hum Genet 2004; 49: 40–45.
Siegsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M et al. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002; 13: 1847–1854.
Motzer RJ, Bander NH, Nanus DM . Renal-cell carcinoma. N Engl J Med 1996; 335: 865–875.
Storkel S, van den BE . Morphological classification of renal cancer. World J Urol 1995; 13: 153–158.
Brauch H, Weirich G, Hornauer MA, Storkel S, Wohl T, Bruning T . Trichloroethylene exposure and specific somatic mutations in patients with renal cell carcinoma. J Natl Cancer Inst 1999; 91: 854–861.
Bruning T, Weirich G, Hornauer MA, Hofler H, Brauch H . Renal cell carcinomas in trichloroethene (TRI) exposed persons are associated with somatic mutations in the von Hippel–Lindau (VHL) tumour suppressor gene. Arch Toxicol 1997; 71: 332–335.
Dhote R, Pellicer-Coeuret M, Thiounn N, Debre B, Vidal-Trecan G . Risk factors for adult renal cell carcinoma: a systematic review and implications for prevention. BJU Int 2000; 86: 20–27.
Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169–174.
Taniguchi S, Mochida Y, Uchiumi T, Tahira T, Hayashi K, Takagi K et al. Genetic polymorphism at the 5′ regulatory region of multidrug resistance 1 (MDR1) and its association with interindividual variation of expression level in the colon. Mol Cancer Ther 2003; 2: 1351–1359.
Meissner K, Sperker B, Karsten C, Zu Schwabedissen HM, Seeland U, Bohm M et al. Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy. J Histochem Cytochem 2002; 50: 1351–1356.
Vogelgesang S, Kunert-Keil C, Cascorbi I, Mosyagin I, Schroder E, Runge U et al. Expression of multidrug transporters in dysembryoplastic neuroepithelial tumors causing intractable epilepsy. Clin Neuropathol 2004; 23: 223–231.
Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.1–RESEARCH0034.11.
Terwilliger JDaOJ . Handbook of Human Genetic Linkage. Johns Hopkins University Press: Baltimore, MD, 1994.
Ernest S, Rajaraman S, Megyesi J, Bello-Reuss EN . Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney. Nephron 1997; 77: 284–289.
Maher JM, Cheng X, Slitt AL, Dieter MZ, Klaassen CD . Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab Dispos 2005; 33: 956–962.
Miller DS . Xenobiotic export pumps, endothelin signaling, and tubular nephrotoxicants – a case of molecular hijacking. J Biochem Mol Toxicol 2002; 16: 121–127.
Bauer B, Hartz AM, Fricker G, Miller DS . Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood–brain barrier. Mol Pharmacol 2004; 66: 413–419.
Denson LA, Auld KL, Schiek DS, McClure MH, Mangelsdorf DJ, Karpen SJ . Interleukin-1beta suppresses retinoid transactivation of two hepatic transporter genes involved in bile formation. J Biol Chem 2000; 275: 8835–8843.
Miller DS, Sussman CR, Renfro JL . Protein kinase C regulation of p-glycoprotein-mediated xenobiotic secretion in renal proximal tubule. Am J Physiol 1998; 275: F785–F795.
Kovacs G, Fuzesi L, Emanual A, Kung HF . Cytogenetics of papillary renal cell tumors. Genes Chromosome Cancer 1991; 3: 249–255.
Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 2002; 72: 572–583.
Meissner K, Jedlitschky G, Meyer zu SH, Dazert P, Eckel L, Vogelgesang S et al. Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacogenetics 2004; 14: 381–385.
Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 2002; 71: 297–303.
Day DA, Tuite MF . Post-transcriptional gene regulatory mechanisms in eukaryotes: an overview. J Endocrinol 1998; 157: 361–371.
Petriz J, Gottesman MM, Aran JM . An MDR-EGFP gene fusion allows for direct cellular localization, function and stability assessment of P-glycoprotein. Curr Drug Deliv 2004; 1: 43–56.
Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359: 30–36.
Hitzl M, Drescher S, van der KH, Schaffeler E, Fischer J, Schwab M et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001; 11: 293–298.
Kim RB . MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. Pharmacogenetics 2002; 12: 425–427.
Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70: 189–199.
Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K . Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001; 11: 175–184.
Itoda M, Saito Y, Soyama A, Saeki M, Murayama N, Ishida S et al. Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5′-untranslated region and exon 28. Drug Metab Dispos 2002; 30: 363–364.
Popowski K, Sperker B, Kroemer HK, John U, Laule M, Stangl K et al. Functional significance of a hereditary adenine insertion variant in the 5′-UTR of the endothelin-1 gene. Pharmacogenetics 2003; 13: 445–451.
Geier A, Mertens PR, Gerloff T, Dietrich CG, En-Nia A, Kullak-Ublick GA et al. Constitutive rat multidrug-resistance protein 2 gene transcription is down-regulated by Y-box protein 1. Biochem Biophys Res Commun 2003; 309: 612–618.
del Moral RG, Olmo A, Aguilar M, O'Valle F . P glycoprotein: a new mechanism to control drug-induced nephrotoxicity. Exp Nephrol 1998; 6: 89–97.
Acknowledgements
The skilful technical assistance of Ingrid Geissler is gratefully acknowledged. We also thank Dr Amke Caliebe and Professor Michael Krawczak, Institute of Medical Informatics and Statistics, UKSH Campus Kiel, Germany, for valuable statistical advice. This work was supported by the German Federal Ministry for Education and Research (01 ZZ 0103).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Haenisch, S., Zimmermann, U., Dazert, E. et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J 7, 56–65 (2007). https://doi.org/10.1038/sj.tpj.6500403
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.tpj.6500403
Keywords
This article is cited by
-
ABCC2 c.-24 C>T single-nucleotide polymorphism was associated with the pharmacokinetic variability of deferasirox in Chinese subjects
European Journal of Clinical Pharmacology (2020)
-
The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions
The Pharmacogenomics Journal (2018)
-
Relationship between ABCB1 3435TT genotype and antiepileptic drugs resistance in Epilepsy: updated systematic review and meta-analysis
BMC Neurology (2017)
-
Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population
The Pharmacogenomics Journal (2017)
-
Are Polymorphisms in Genes Relevant to Drug Disposition Predictors of Susceptibility to Drug-Induced Liver Injury?
Pharmaceutical Research (2017)